货号:GS40546
Picankibart (IBI112) is a fully humanized, IgG1-kappa monoclonal antibody developed by Innovent Biologics. Approved in China in November 2025, it is indicated for the treatment of moderate-to-severe plaque psoriasis. Its key clinical feature is an engineered long half-life, allowing for a maintenance dosing interval of once every 12 weeks after initial loading doses.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物